The Priority Review

The stream · Daily digest

The stream: Thursday, October 15, 2026

13 briefs from ClinicalTrials.gov and the Federal Register, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 8

  1. Pfizer registers Phase 3 trial of PF-08653944 in Chinese adults with overweight or obesity

    The study plans to enroll an estimated 432 participants and compares berobenatide (PF-08653944) with placebo. It is scheduled to start on October 15, 2026, with primary completion expected on June 6, 2028.

    Source: ClinicalTrials.gov registry record, October 15, 2026

  2. Hinova registers Phase 3 trial of Deutenzalutamide in high-risk BCR prostate cancer

    Hinova Pharmaceuticals Inc. has registered a Phase 3, randomized, double-blind, placebo-controlled study of Deutenzalutamide plus androgen deprivation therapy versus placebo plus ADT in patients with high-risk biochemical recurrence of prostate cancer. The study plans to enroll 1044 participants and is expected to start on October 31, 2026, with primary completion projected for December 31, 2029.

    Source: ClinicalTrials.gov registry record, October 15, 2026

  3. Onconic registers Phase 3 trial of JP-1366-based triple therapy for H. Pylori

    The study, led by Onconic Therapeutics Inc., plans to enroll 414 participants and begin recruiting on November 1, 2026. It is a multicenter, randomized, double-blind, active-controlled Phase III trial to evaluate the efficacy and safety of JP-1366-based triple therapy in H. Pylori-positive subjects.

    Source: ClinicalTrials.gov registry record, October 15, 2026

  4. Merck registers Phase 3 trial of ensifentrine for COPD exacerbation prevention

    Merck Sharp & Dohme LLC has registered a Phase 3, randomized, double-blind, placebo-controlled study (ENHANCE-3) to evaluate ensifentrine (MK-5884) for preventing moderate and severe COPD exacerbations. The trial plans to enroll 2136 participants, begin on October 23, 2026, and reach primary completion on April 29, 2029.

    Source: ClinicalTrials.gov registry record, October 15, 2026

  5. Sanofi posts results of Phase 3 itepekimab trial in COPD

    The Phase 3 study, NCT04701983 (AERIFY-1), enrolled 1127 participants and completed primary data collection on April 11, 2025. Results were first posted on ClinicalTrials.gov on October 15, 2026.

    Source: ClinicalTrials.gov results record, October 15, 2026

  6. United Therapeutics posts results of Phase 3 TETON-2 inhaled treprostinil study

    The study enrolled 597 participants and completed primary data collection on June 30, 2025. Results were first posted on ClinicalTrials.gov on October 15, 2026.

    Source: ClinicalTrials.gov results record, October 15, 2026

  7. ACADIA posts results of Phase 3 carbetocin nasal spray trial in Prader-Willi syndrome

    The study, completed in August 2025, enrolled 175 participants and evaluated carbetocin nasal spray versus placebo over 12 weeks. Results were first posted on ClinicalTrials.gov on October 15, 2026.

    Source: ClinicalTrials.gov results record, October 15, 2026

  8. Vertex posts results of Phase 3 ELX/TEZ/IVA study in infants

    Vertex Pharmaceuticals Incorporated posted results of a completed Phase 3, open-label study evaluating the pharmacokinetics, safety, tolerability, pharmacodynamics, and efficacy of ELX/TEZ/IVA in cystic fibrosis participants 12 to less than 24 months of age. The study enrolled 67 participants and began on June 27, 2023, with primary completion on September 4, 2025.

    Source: ClinicalTrials.gov results record, October 15, 2026

Approvals · 2

  1. EMA recommends authorisation of Rasonque for metastatic pancreatic cancer

    EMA's CHMP has recommended granting a marketing authorisation for Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior treatment. The recommendation follows a phased review that shortened assessment to less than 150 days, with Rasonque showing a median overall survival of 12.4 months versus 6.7 months for chemotherapy in a phase 3 study of 500 patients.

    Source: EMA news release, October 15, 2026

  2. CHMP adopts positive opinion on Rasonque for metastatic pancreatic cancer

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 15 October 2026, recommending marketing authorisation for Rasonque, a daraxonrasib monotherapy for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The product will be available as 100 mg and 150 mg film-coated tablets and is designated as an orphan medicine.

    Source: EMA medicine page (CHMP opinion), October 15, 2026

Policy · 2

  1. $78 million for rural Texas health workforce and chronic disease prevention

    The Trump Administration announced $78 million in Rural Health Transformation Program funding to 216 rural healthcare providers through the Rural Texas Strong initiative. The investment will support chronic disease prevention, workforce recruitment and retention, and upgrades to medical equipment and facilities across Texas.

    Source: CMS press release, October 15, 2026

  2. MiniMed completes separation from Medtronic

    MiniMed announced on Oct. 15, 2026 that it has completed its separation from Medtronic, becoming a fully independent company. Medtronic accepted 55,032,401 Medtronic ordinary shares in exchange for 252,813,348 shares of MiniMed common stock, a 5.4x subscribed offer.

    Source: Company press release (PR Newswire), October 15, 2026

Regulation · 1

  1. FDA authorizes emergency use of four animal drugs for New World screwworm

    The FDA issued four Emergency Use Authorizations for products requested by Elanco US Inc., Zoetis Inc., Bimeda Animal Health Ltd., and Sergeant's Pet Care Products LLC to prevent infestations caused by New World screwworm larvae in various animals. The authorizations follow a HHS determination on August 18, 2025 that circumstances justify emergency use.

    Source: Federal Register notice, October 15, 2026